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A b s t r a c t
Introduction: There are limited data on the comparison of bioresorbable vascular scaffold (BVS) and drug-eluting stent (DES)/
bare-metal stent (BMS) implantation in an unselected population of patients with coronary artery disease.
Aim: To compare the periprocedural outcomes and patient profile of BVS and DES/BMS implantation in an all-comer population 
from the ORPKI Polish National Registry.
Material and methods: A total of 141,324 consecutive patients from 151 invasive cardiology centers in Poland were included 
in this prospective registry between January 2014 and June 2015. Periprocedural data on patients with at least one BVS (Absorb, 
Abbott Vascular, Santa Clara, CA, USA), DES or BMS (all available types) implantation in de novo lesions during index percutaneous 
coronary intervention for stable angina (SA) or acute coronary syndrome were collected.
Results: Bioresorbable vascular scaffold was the most often used in patients with SA, in single-vessel disease and in younger 
male patients. Bioresorbable vascular scaffold implantation was significantly more often associated with periprocedural adminis-
tration of ticagrelor/prasugrel (6.8% vs. 3.6%; p = 0.001) and use of intravascular ultrasound and optical coherence tomography in 
comparison with the DES/BMS group (2.8% vs. 0.6% and 1.8% vs. 0.1%, respectively; p = 0.001 for both). The incidence of peripro-
cedural death was significantly lower in the BVS group than the DES/BMS group (0.04% vs. 0.32%; p = 0.02), but this difference was 
no longer significant after adjustment for covariates. On the other hand, coronary artery perforation occurred significantly more 
often during BVS delivery (0.31% vs. 0.12%; p = 0.01), and BVS implantation was identified as an independent predictor of coronary 
artery perforation in multivariate logistic regression analysis (OR = 6.728, 95% CI: 2.394–18.906; p = 0.001). 
Conclusions: Patients treated with BVS implantation presented an acceptable safety and efficacy profile in comparison with the 
DES/BMS group. However, lower risk patients were the most frequent candidates for BVS implantation. 
Key words: bioresorbable vascular scaffold, metallic platforms, all-comers, de novo lesions, stable angina, acute coronary syn-
drome, registries.
Introduction
Current guidelines recommend coronary stenting 
with new-generation drug-eluting stents (DES) for most 
indications of percutaneous coronary intervention (PCI) 
[1]. However, new-generation DES have not managed to 
address all the limitations of metallic stents [1]. These 
limitations may include caging of the vessel, impairment 
of vasomotion, chronic inflammation, late expansive re-
modeling, late thrombosis, potential preclusion of sur-
gical revascularization and interference with magnetic 
resonance, imaging causing the blooming effect [2–6]. 
A bioresorbable vascular scaffold (BVS) ensures tempo-
rary vessel support with drug delivery to the endothelium 
without the potential long-term limitations of permanent 
metallic platforms [4, 5]. Results from the ABSORB tri-
als have confirmed the safety and efficacy of BVS im-
plantation in rather non-complex lesions [7]. However, 
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there are still limited data on BVS versus metallic stent 
implantation in an unselected ”real-world” population, 
both in terms of current use profile and periprocedural 
outcomes. 
Aim
The aim of this study was to compare the periproce-
dural outcomes and patient profiles of BVS and DES/BMS 
implantation in an all-comer population from the ORPKI 
Polish National Registry.
Material and methods
All obtained data were stored in the electronic da-
tabase of National PCI Registry (ORPKI) operated by the 
Jagiellonian University Medical College in Krakow. ORPKI 
is a  national registry collecting data on all percutane-
ous procedures in interventional cardiology performed 
in Polish ORPKI is a national registry collecting data on 
all percutaneous procedures in interventional cardiology 
performed on Polish territory [8]. This registry is a  sin-
gle-arm prospective observational study. Between Janu-
ary 2014 and June 2015, it enrolled 141,324 consecutive 
patients from 151 invasive cardiology centers in Poland. 
Patients with at least one BVS (Absorb, Abbott Vascular, 
Santa Clara, CA, USA), DES or BMS (all available types) 
implantation in de novo lesions during index PCI for 
stable angina (SA) or acute coronary syndrome (ACS) 
were included. A flow chart of the patients is presented 
in Figure 1 A. All procedures were carried out according 
to current standards of PCI. No further evaluation or fol-
low-up was performed after hospital discharge. The full 
range of sizes and lengths for both BVS and DES/BMS 
were available during the study period in all participat-
ing centers. The decision to implant a BVS rather than 
a DES/BMS was the operator’s choice according to stent 
instructions. However, it was recommended for the pur-
pose of this registry to qualify for Absorb BVS implanta-
tion according to a prespecified algorithm (Figure 1 B). 
Adverse events were diagnosed at the operator’s discre-
tion according to definitions in current ESC guidelines. 
The Independent Clinical Endpoint Committee was not 
involved in adverse events classification and validation 
of definitions. All patients provided informed consent for 
the procedure. The study complied with ethical principles 
for clinical research based on the Declaration of Helsinki 
with later amendments. No funding was used to support 
this registry.
Statistical analysis
Standard descriptive statistics were used in the anal-
ysis. Quantitative variables were described using mean ± 
standard deviation. Categorical variables were presented 
282 136 consecutive patients collected prospectively from  
151 invasive cardiology centres in Poland between January 2014  
and June 2015 (ORPKI registry)
141 324 patients included  
in study analysis
140 812 patients excluded  
from study analysis
Patients with at least one 
BVS, DES or BMS  
implantation in de novo 
lesions during index PCI  
in SA or ACS
Exclusion criteria:
 – Stent restenosis/throm-
bosis (n = 8780)
 – Treated with only POBA/
DEB (n = 2141)
 – Without PCI and stent im-
plantation (n = 114 008)
 – No information about 
type of stent (n = 15 883)
A B
Algorithm of the patient’s qualification for ABSORB BVS  
implantation
1. Patients < 67 year old, or older, but active style of life.  Yes  No 
2. Significant risk of future revascularizations Yes  No 
– diffused disease or long lesions,
– multiple non-significant stenoses,
– multiple risk factors,
to facilitate/having the option for the future interventions
(both percutaneous and cardiosurgery).
3. Long lesions for PCI to avoid “full metal jacket” Yes  No 
4. Lesions with location of potential coronary Yes  No  
by-pass placement:
– middle segment LAD,
– distal segments of RCA, Cx,
– middle, distal segments of OM.
5. Lesions “on the bend” to avoid straightening Yes  No  
natural curvature of the artery.
6. Multivessel CAD qualified for PCI,  Yes  No  
especially patients, who have a high probability  
of full revascularization with bioresorbable scaffolds  
or partial revascularization, but in prognostically  
important localizations (proximal segments, LAD,  
potential by-pass localization).
Please consider to use the ABSORB BVS in the case of any above 
criteria is fulfilled and if there is no angiographic contradictions for 
the use of ABSORB BVS.
Figure 1. Flow chart of the patients (A) and algorithm of the patient’s qualification for ABSORB BVS implan-
tation (B)
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as counts and percentages. The level of statistical signifi-
cance was set at p < 0.05. The Mann-Whitney U test (for 
non-normal distribution of data) or unpaired (two-sam-
ple) Student’s t-test (for normally distributed data) was 
applied for continuous variables. The c2 test was used for 
categorical (nominal and dichotomous) variables. In ad-
dition, multivariate logistic regression analysis was per-
formed to find independent predictors of periprocedural 
death and perforation of the coronary artery. Forward 
selection in logistic regression analysis with a probabil-
ity value for covariates to enter the model was set at 
the 0.05 level. All baseline and procedural characteristics 
were tested. Results were presented as odds ratios (OR) 
with 95% confidence intervals (CI). All analyses were car-
ried out with Statistica 10 (StatSoft, Inc. Tulsa, OK, USA).
Results
Scaffold implantation was performed in 2,258 pa-
tients. Metallic stents were used in 139,066 procedures. 
Bioresorbable vascular scaffold was more often used in 
patients with SA, in single-vessel disease and in young-
er male patients (Tables I  and II). Diabetes mellitus, 
arterial hypertension, previous stroke, chronic kidney 
disease and previous coronary artery bypass grafting 
were significantly less frequently reported in patients 
with BVS implantation as compared to the DES/BMS 
group. Incidence of BVS delivery to the left anterior de-
scending (LAD) coronary artery was significantly higher 
as compared to the DES/BMS group (54.3% vs. 35.9%; 
p = 0.001). The right radial access was the most common 
during PCI, with a higher rate of its use in BVS patients 
as compared to DES/BMS patients (62.5% vs. 50.2%; 
p = 0.001). Overall, 165,188 metallic stents were implant-
ed in the DES/BMS group (145,472 (88.1%) DES; 19,716 
(11.9%) BMS; 3,355 (2%) DES and BMS simultaneously 
in one patient) and 2,407 biodegradable scaffolds in the 
BVS group. No differences were found between groups 
in terms of mean number of deployed stents per pa-
tient (BVS vs. DES/BMS: 1.07 ±0.3 vs. 1.09 ±0.6; p = 0.9). 
Most often one scaffold was implanted in the BVS group 
(94%), two were delivered in 5.5%, three in 0.4% and 
four in 0.4% of all cases. Data describing the number of 
delivered scaffolds or stents to particular vessels are pre-
sented in Table III. No BVS implantation was reported in 
48 (31.8%) participating centers. Experience with 1–10 
devices was noted in 63 (41.7%), 10–50 were used in 29 
(19.2%) and 50–100 scaffolds were deployed in 5 (3.3%) 
Table I. Baseline patient characteristics
Parameter BVS (N = 2,258) DES and BMS (N = 139,066) P-value
Male gender 1,597 (70.7%) 93,846 (67.5%) 0.001
Age [years] 59.97 ±10.6 66.79 ±10.8 0.001
Diabetes mellitus 437 (19.4%) 37,989 (27.3%) 0.001
Previous stroke 37 (1.6%) 4,666 (3.4%) 0.001
Previous MI 645 (28.6%) 39,802 (28.6%) 0.9
Previous CABG 75 (3.3%) 7,979 (5.7%) 0.001
Previous PCI 856 (37.9%) 45,119 (32.4%) 0.001
Smoking 517 (22.9%) 27,997 (20.1%) 0.002
Arterial hypertension 1,581 (70.0%) 100,494 (72.3%) 0.02
CKD 50 (2.2%) 7311 (5.3%) 0.001
BMS – bare metal stent, BVS – bioresorbable vascular scaffold, CABG – coronary artery bypass grafting, CKD – chronic kidney disease, DES – drug-eluting stent, 
MI – myocardial infarction, PCI – percutaneous coronary intervention.
Table II. Indications for percutaneous coronary in-
tervention (p = 0.001 for all comparisons)
Parameter BVS  
(N = 2,247)
DES and BMS  
(N = 138,440)
SA 1,169 (52) 49,581 (35.8)
UA 562 (25) 35,384 (25.6)
STEMI 256 (11.4) 29,662 (21.4)
NSTEMI 260 (11.6) 23,813 (17.2)
CTO 54 (2.4) 431 (0.3)
Bifurcation 72 (3.2) 7840 (5.7)
BVS  
(N = 1,715)
DES and BMS  
(N = 114,356)
Single-vessel disease 1,150 (67.1) 54,882 (48.0)
LMCA 6 (0.4) 137 (0.1)
Multi-vessel disease 
without LMCA
530 (30.8) 53,678 (47.0)
Multi-vessel disease 
with LMCA
29 (1.7) 5,659 (4.9)
BMS – bare metal stent, BVS – bioresorbable vascular scaffold, CTO – chron-
ic total occlusion, DES – drug-eluting stent, LMCA – left main coronary artery, 
NSTEMI – non-ST-segment elevation myocardial infarction, SA – stable angina, 
STEMI – ST-segment elevation myocardial infarction, UA – unstable angina.
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participating catheterization laboratories. Over 100 BVS 
were delivered in only 6 (4.0%) highly experienced inva-
sive cardiology centers. The highest volume was repre-
sented by a catheterization laboratory with implantation 
of 190 scaffolds. A higher number of BVS utilization was 
noted in 2015 in comparison with corresponding months 
of 2014. The lowest scaffold deployment was reported 
during July-August and at the end of 2014. The mean 
number of implanted scaffolds was 21.9 ±183.9 per cath-
eterization laboratories with experience in BVS utiliza-
tion. Periprocedural therapy used during PCI is shown 
in Table IV. Thrombolysis in Myocardial Infarction flow 
before and after PCI is demonstrated in Figure 2. Biore-
sorbable vascular scaffold implantation was significantly 
Table III. Number of scaffolds or stents implanted in particular vessels
Parameter BVS (N = 2,407)
n (%)
BMS (N = 19,716) DES (N = 145,472) P-value
LMCA 15 (0.6) 251 (1.2) 3,652 (2.5) 0.001
LAD 1,306 (54.3) 4,726 (24.0) 54,630 (37.6) 0.001
Cx 538 (22.4) 5,065 (25.8) 36,970 (25.4) 0.001
RCA 538 (22.4) 9,497 (48.2) 48,369 (33.3) 0.001
LIMA/RIMA 2 (0.1) 18 (0.1) 295 (0.2) 0.001
SvG 8 (0.3) 159 (0.8) 1,556 (1.1) 0.001
BMS – bare metal stent, BVS – bioresorbable vascular scaffold, Cx – circumflex, DES – drug-eluting stent, LAD – left anterior descending, LIMA/RIMA – left/right 
internal mammary artery, SvG – saphenous vein grafts, RCA – right coronary artery.
Table IV. Percutaneous coronary intervention details
Parameter BVS (N = 2,258) DES and BMS (N = 139,066) P-value
Radiation dose [mGy] 1,144.6 ±852.2 1,171.4 ±1,008.6 0.02
Contrast volume [ml] 169.2 ±69.7 178.4 ±77.6 0.001
IVUS 63 (2.8%) 817 (0.6%) 0.001
OCT 40 (1.8%) 132 (0.1%) 0.001
Rotablation 5 (0.2%) 610 (0.4%) 0.1
Aspiration thrombectomy 65 (2.9%) 5,991 (4.3%) 0.001
Aspiration thrombectomy in STEMI patients 42 (16.4%) 5,115 (16.4%) 1.0
Antiplatelet and antithrombotic therapy:
ASA administered during PCI 647 (28.7%) 45,095 (32.4%) 0.001
P2Y
12
 inhibitors before and during PCI 2,258 139,066 0.001
Clopidogrel 2,106 (93.2%) 134,124 (96.4%) 0.001
Ticagrelor 99 (4.4%) 3,899 (2.8%) 0.001
Prasugrel 53 (2.4%) 1,043 (0.8%) 0.001
GP IIb/IIIa inhibitors 11 (0.5%) 413 (0.3%) 0.1
Abciximab 2 (18.2%) 142 (34.4%) 0.1
Eptifibatide 9 (91.8%) 257 (62.2%) 0.1
Tirofiban 0 (0.0%) 14 (3.4%) 0.1
UFH 2,034 (90.1%) 118,440 (85.2%) 0.001
Bivalirudin 8 (0.4%) 1,041 (0.8%) 0.03
LMWHs 79 (3.5%) 5,476 (3.9%) 0.3
ASA – acetylsalicylic acid, BMS – bare metal stent, BVS – bioresorbable vascular scaffold, DES – drug-eluting stent, FFR – fractional flow reserve, IVUS – intravascular 
ultrasound, LMWHs – low-molecular-weight heparins, OCT – optical coherence tomography, UFH – unfractionated heparin, GP – glycoprotein.
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more frequently associated with periprocedural adminis-
tration of ticagrelor/prasugrel (6.8% vs. 3.6%; p = 0.001) 
and use of intravascular ultrasound (IVUS) and optical 
coherence tomography (OCT) in comparison with the 
DES/BMS group (2.8% vs. 0.6% and 1.8% vs. 0.1%, re-
spectively; p = 0.001 for both). There were no differences 
between the BVS group and the DES/BMS group in terms 
of incidence of periprocedural events such as myocardial 
infarction (0.0% vs. 0.1%; p = 0.1), no-reflow (0.35% vs. 
0.45%; p = 0.5), vascular access site bleeding (0.09% vs. 
0.12%; p = 0.7), sudden cardiac arrest (0.2% vs. 0.4%; 
p = 0.2) or allergic reactions (0.09% vs. 0.15%; p = 0.4). 
Higher incidence of perforation of coronary artery was 
reported in the BVS group (0.31% vs. 0.12%; p = 0.01), 
but periprocedural death occurred less frequently in pa-
tients treated with BVS (0.04% vs. 0.32%; p = 0.02). In 
the logistic regression analysis age (OR = 1.028, 95% CI: 
1.006–1.05; p = 0.01) and BVS implantation (OR = 6.728, 
95% CI: 2.394–18.906; p = 0.001) were identified as inde-
pendent predictors of perforation of the coronary artery. 
On the other hand, male gender (OR = 0.525, 95% CI: 
0.326–0.847; p = 0.008) and TIMI class before PCI (OR = 
0.784 per 1 class increase, 95% CI: 0.65–0.945; p = 0.01) 
were considered to decrease the risk of this adverse 
event. No significant impact of rotablation was found 
(OR = 7.201, 95% CI: 0.968–53.562; p = 0.054). Male gen-
der (OR = 7.502, 95% CI: 2.045–27.523; p = 0.002), age 
(OR = 1.024, 95% CI: 1.01–1.039; p = 0.001), diabetes 
mellitus (OR = 1.609, 95% CI: 1.13–2.291; p = 0.008), car-
diogenic shock at admission to the catheterization labo-
ratory (OR = 33.689, 95% CI: 24.366–46.579; p = 0.001), 
previous stroke (OR = 1.834, 95% CI: 1.072–3.138; 
p = 0.03) and myocardial infarction in past medical 
history (OR = 2.395, 95% CI: 1.587–3.614; p = 0.001) 
were significant predictors of periprocedural death. Ar-
terial hypertension (OR = 0.561, 95% CI: 0.402–0.782; 
p = 0.001) and TIMI class before PCI (OR = 0.547 per 
1 class increase, 95% CI: 0.468–0.639; p = 0.001) cor-
related negatively with the risk of mortality during PCI.
Discussion
Patients with a lower risk profile were the most fre-
quent candidates for BVS implantation. The presented 
results are consistent with the main criteria of the algo-
rithm used for patient’s qualification for Absorb BVS im-
plantation (Figure 1 B). To our best knowledge, this regis-
try is to date the largest multicentre report of everyday 
usage of BVS in “real-world” settings. Indications for PCI 
with BVS were comparable to those reported in the 
GHOST-EU registry [9]. However, our registry included 
less ST-elevated myocardial infarction(STEMI)/non ST-el-
evated myocardial infarction (NSTEMI) in favor of pa-
tients with unstable angina. The safety and efficacy of 
BVS implantation with very good procedure results in 
both ACS and SA have been presented in several studies 
[9–13]. In our registry treatment of lesions in the middle 
and distal portion of the LAD was seen as a particularly 
strong indication for use of BVS over a metallic stent in 
order to reduce limitation in future PCI or bypass grafting 
by left internal mammary artery utilization. As previously 
suggested, younger patients were considered to have the 
greatest theoretical benefit over a permanent stent in cu-
mulative reduction of the risk of late scaffold thrombosis 
(ScT) [13]. A  similar observation regarding selection of 
patients and lesions for BVS implantation has been pre-
sented in a few large studies [2, 9]. Patient selection for 
Figure 2. Thrombolysis in myocardial infarction before (A) and after (B) percutaneous coronary intervention
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BVS implantation in this registry was consistent with the 
main criteria of recommendations from both a European 
and a Netherlands consensus [14, 15], which indicate the 
highest beneficial effect on longtime clinical outcome af-
ter scaffold deployment. Procedural success depends not 
only on proper selection of patients but also lesions [16]. 
Several studies have suggested benefit from intracoro-
nary imaging with IVUS and/or OCT for optimization of 
PCI results [17]. However, according to the European con-
sensus it is not routinely recommended for this purpose 
[15]. Intravascular ultrasound is used for the evaluation 
of the plaque morphology and in the preparation phase. 
Optical coherence tomography allows better optimiza-
tion of scaffold deployment. In addition, it could be more 
useful in complex lesions or bifurcations [18]. Several 
studies have presented high variability in intravascular 
imaging utilization during PCI with BVS deployment [9, 
19–21]. Our registry showed lower frequency of OCT and 
IVUS utilization in comparison with most of the 
above-mentioned studies. However, rates of imaging use 
were similar to those reported in the previous Polish na-
tional registry of BVS implantation [2]. Vessel visualiza-
tion with these procedures was not mandatory, but it 
was performed in difficult cases with a questionable re-
sult of scaffold deployment. According to the European 
consensus, the new users of BVS should have a  lower 
threshold for the use of imaging before and after BVS 
implantation [15]. Increased risk of ScT and myocardial 
infarction were early concerns raised with introduction of 
BVS utilization. The GHOST-EU registry presented cumu-
lative incidence of definite/probable ScT of 1.5% at 30 
days and 2.1% at 6 months (most of the cases occurred 
during 30 days after PCI) [9]. Further analysis revealed 
that 20 of 23 patients with ScT were on dual antiplatelet 
therapy (DAPT) at the time of thrombosis [22]. Early 
events were mostly attributable to procedural issues (i.e., 
dissection, incomplete scaffold apposition or expansion), 
and late events are more likely linked to scaffold-related 
factors and vascular responses [22]. The ScT rate after 
BVS delivery was also higher than for metallic stents in 
other “real-world” registries (3.0% in the AMC registry 
[23], 1.3% in the Registro Absorb Italiano registry [24] – 
preliminary data). However, the rate of ScT was not high-
er in the largest, most recent randomized controlled clin-
ical trial [25]. Higher prevalence of thrombosis was 
reported in the first 30 days after implantation, similar to 
the frequency distribution for metallic stents [22]. To re-
duce the ScT rate, thorough selection of lesions and PCI 
techniques, more aggressive plaque modification before 
BVS implantation, routine high-pressure non-compliant 
balloon post-dilatation to ensure adequate scaffold ex-
pansion and more frequent use of intravascular imaging 
to optimize lesion coverage and scaffold dimensions was 
recommended [22, 26]. On the other hand, extensive and 
time-consuming lesion preparation might lead to peripro-
cedural myocardial infarction, coronary dissection or 
even vessel perforation [17]. In this registry incidence of 
perforation of coronary artery during BVS delivery was 
significantly higher in comparison with the metallic stent 
group. In the previous Polish national registry dissection 
occurred in 2.9% of all cases [2]. Another study demon-
strated perforation of coronary arteries in 0.73% of in-
cluded patients [27]. The results of our logistic regression 
analysis may support the idea of a  possible impact of 
extensive lesion preparation before BVS implantation on 
increased risk of coronary artery perforation. In our study 
patients with a lower risk profile were the most frequent 
candidates for BVS implantation, which might be the rea-
son for significantly lower periprocedural mortality in 
this group. This positive impact of BVS on periprocedural 
mortality was no longer significant after adjustment for 
covariates. Importantly, cardiogenic shock at admission 
to the catheterization laboratory was the strongest pre-
dictor of periprocedural death. A  recent meta-analysis 
reported periprocedural myocardial infarction (according 
to the Society of Cardiac Angiography and Interventions 
criteria) in 0.8% of patients with BVS implantation [26]. 
In our study no periprocedural myocardial infarction was 
reported in the BVS group. The incidence of MI was low, 
probably due to inclusion of periprocedural events only. 
In a recent meta-analysis [28] patients treated with BVS 
implantation had a similar risk of myocardial infarction 
(OR = 1.36, 95% CI: 0.98–1.89; p = 0.06) and death (OR = 
0.95, 95% CI: 0.45–2.00; p = 0.89) but with higher risk of 
define/probable ScT (OR = 1.99, 95% CI: 1.00–3.98; p = 
0.05), especially between 1 and 30 days after implanta-
tion (OR = 3.11, 95% CI: 1.24–7.82; p = 0.02) as com-
pared to the metallic stent group [28]. However, Cassese 
et al. did not evaluate target vessel myocardial infarction 
(TVMI), which was significantly higher for BVS in compar-
ison to conventional stents in data presented in two oth-
er meta-analyses [26, 29, 30]. Also, Cassese et al. did not 
discuss the numerically higher (but not statistically sig-
nificant) prevalence of any-cause myocardial infarction in 
BVS patients (5.2% vs. 3.5%; p = 0.06). Lipinski et al. 
also reported that patients who received a BVS were at 
a higher risk of myocardial infarction (OR = 2.06, 95% CI: 
1.31–3.22, p = 0.002) and definite/probable ScT (OR = 
2.06, 95% CI: 1.07–3.98, p = 0.03) compared with the 
metallic stent group, whereas there was a lower (but not 
at the level of statistical significance) all-cause mortality 
with a BVS (OR = 0.40, 95% CI: 0.15–1.06, p = 0.06) [31]. 
This meta-analysis was limited by methodology that 
mixed SA and STEMI, single-arm registries and random-
ized trials, and included unpublished, non-peer reviewed 
registries [22, 30]. In a  recent patient-level, pooled me-
ta-analysis of four randomized studies, TVMI was in-
creased with BVS compared with DES (OR = 1.45, 95% CI: 
1.02–2.07; p = 0.04), due in part to non-significant in-
creases in periprocedural myocardial infarction and de-
vice thrombosis with BVS (OR = 2.09, 95% CI: 0.92–4.75, 
p = 0.08) [26]. The relative rates of all-cause and cardiac 
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mortality and all-cause myocardial infarction did not dif-
fer between BVS and metallic stents [26]. Also data from 
the meta-analysis by Banach et al. were not able to de-
tect statistically significant differences in 1-year out-
comes between BVS and metallic stents [30]. The results 
showed significantly increased risk of TVMI between BVS 
and conventional stents (OR = 1.45, 95% CI: 1.03–2.05; 
p = 0.03) [29]. No other significant differences between 
BVS and conventional stents were reported except any-
cause myocardial infarction (OR = 1.36, 95% CI: 1.00–
1.85, p = 0.049) [29]. Furthermore, BVS might provide 
intrinsically less kinetic support than metallic stents, es-
pecially 6 to 12 months after implantation when the ra-
dial strength is diminished as a consequence of resorp-
tion kinetics [31]. This might be responsible for the 
numerically higher risk of any-cause myocardial infarc-
tion with BVS versus metallic stents implantation and 
the significant increase of TVMI reported in a few meta- 
analyses. Furthermore, BVS might entrap more throm-
botic content between the vessel and the scaffold, be-
cause of the larger wall surface coverage and the greater 
strut thickness than the current thin-strut DES [29]. On 
the other hand, it might lead to an increased incidence of 
ScT after BVS implantation. Administration of proper an-
tiplatelet drugs seems to be crucial for optimal clinical 
results and a low rate of ScT after BVS implantation [29]. 
In a  large “real-world” registry antiplatelet therapy was 
prescribed at discharge in all patients and recommended 
for at least 12 months in 93.6% of them [9]. Clopidogrel, 
prasugrel and ticagrelor were prescribed in 73.2%, 26.2% 
and 0.6% of patients, respectively [9]. A recent patient-lev-
el, pooled meta-analysis presented prasugrel or ticagrelor 
utilization in 24% of patients with BVS implantation [26]. 
A  lower rate of newer antiplatelet drug administration 
during the procedure was reported in our registry in com-
parison with above-mentioned studies; however, newer 
antiplatelet agents were significantly more often admin-
istered in BVS implantation in comparison with DES/
BMS. This result is in line with current recommendations 
for antiplatelet therapy after BVS implantation [14, 15]. 
The present data might also be considered as a marker of 
preferences of BVS and antiplatelet therapy utilization in 
particular invasive cardiology centers in Poland. 
The main limitation of this prospective observational 
study is its non-randomized design and all the known 
drawbacks of single-arm registry studies. The analysis 
included all available types of DES and BMS. Comparison 
with new-generation DES may be more appropriate to 
evaluate the safety and efficacy of BVS implantation. The 
possibility of the results being affected by unknown con-
founding factors cannot be excluded. There is a potential 
bias caused by the lack of in-hospital and long-term fol-
low-up data in terms of clinical endpoints. There is a lack 
of angiographic data describing lesion type and morphol-
ogy. Detailed data on device types and sizes were also 
not provided in the ORPKI registry.
The relatively small sample size of patients with BVS 
implantation and low incidence of adverse events sug-
gest that our study should be considered exploratory and 
hypothesis generating. 
Conclusions
Patients treated with BVS implantation presented 
an acceptable safety and efficacy profile in comparison 
with the DES/BMS group. Lower risk patients were the 
most frequent candidates for BVS implantation. Scaffold 
implantation might be associated with higher risk of cor-
onary artery perforation. Periprocedural administration 
of ticagrelor/prasugrel and use of intravascular imaging 
were significantly higher in the BVS group in comparison 
with DES/BMS. 
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